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Background: Late onset bipolar disorder (LOBD) is often difficult to distinguish from
degenerative dementias, such as Alzheimer disease (AD), due to comorbidities and
common cognitive symptoms. Moreover, LOBD prevalence in the elder population is not
negligible and it is increasing. Both pathologies share pathophysiological neuroinflamma-
tion features. Improvements in differential diagnosis of LOBD and AD will help to select
the best personalized treatment.
Objective: The aim of this study is to assess the relative significance of clinical observa-
tions, neuropsychological tests, and specific blood plasma biomarkers (inflammatory and
neurotrophic), separately and combined, in the differential diagnosis of LOBD versus AD. It
was carried out evaluating the accuracy achieved by classification-based computer-aided
diagnosis (CAD) systems based on these variables.
Materials: A sample of healthy controls (HC) (n=26), AD patients (n=37), and LOBD
patients (n=32) was recruited at the Alava University Hospital. Clinical observations,
neuropsychological tests, and plasma biomarkers were measured at recruitment time.
Methods: We applied multivariate machine learning classification methods to dis-
criminate subjects from HC, AD, and LOBD populations in the study. We analyzed,
for each classification contrast, feature sets combining clinical observations, neu-
ropsychological measures, and biological markers, including inflammation biomark-
ers. Furthermore, we analyzed reduced feature sets containing variables with signi-
ficative differences determined by a Welch’s t-test. Furthermore, a battery of classi-
fier architectures were applied, encompassing linear and non-linear Support Vector
Machines (SVM), Random Forests (RF), Classification and regression trees (CART), and
their performance was evaluated in a leave-one-out (LOO) cross-validation scheme.
Post hoc analysis of Gini index in CART classifiers provided a measure of each variable
importance.
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Results: Welch’s t-test found one biomarker (Malondialdehyde) with significative
differences (p<0.001) in LOBD vs. AD contrast. Classification results with the best
features are as follows: discrimination of HC vs. AD patients reaches accuracy 97.21%
and AUC 98.17%. Discrimination of LOBD vs. AD patients reaches accuracy 90.26%
and AUC 89.57%. Discrimination of HC vs LOBD patients achieves accuracy 95.76%
and AUC 88.46%.
Conclusion: It is feasible to build CAD systems for differential diagnosis of LOBD and AD
on the basis of a reduced set of clinical variables. Clinical observations provide the greatest
discrimination. Neuropsychological tests are improved by the addition of biomarkers, and
both contribute significantly to improve the overall predictive performance.
Keywords: late onset bipolar disorder, Alzheimer’s disease, computer-aided diagnosis, clinical, neuropsychologi-
cal, and blood, biomarkers, pharmacological
1. INTRODUCTION
Bipolar disorder (BD) is a chronic mood disorder associated with
cognitive, affective, and functional impairment, often appearing
at youth (around age 20 years), or even earlier, whose age of
onset may be determined by environmental conditions (Bauer
et al., 2014b, 2015a,b; Martinez-Cengotitabengoa et al., 2014).
Dementia syndrome arising after a lifetime history of bipolarity
(Lebert et al., 2008; Ng et al., 2008) does not match the criteria
of Alzheimer’s disease (AD) (Forcada et al., 2014). On the other
hand, late onset (i.e., age> 50 years) of BD (LOBD) (Depp and
Jeste, 2004; Prabhakar and Balon, 2010; Besga et al., 2011; Carlino
et al., 2013; Po-Han et al., 2015) may be difficult to differentiate
from behavioral impairment associated with Alzheimer’s disease
(AD), because of overlapping symptoms and neuropathology.
Though AD and LOBD are considered distinct and unrelated
clinical entities, there is a trend in recent years to questionwhether
there is a link between both disorders based on the overlapping
symptoms and the increased successful use of well-established
BD treatments, i.e., Lithium, to treat dementia (Takeshi et al.,
2006).
1.1. Common Traits Between LOBD and AD
Most studies focus on the differences and commonalities between
BD and schizophrenia (García-Bueno et al., 2014), and depression
(Azorin et al., 2015); however, some recent studies report compar-
isons between BD and AD patients (Berridge, 2013) due to either
late onset or BD aging population. Inflammation and oxidative
stress have been found as common pathophysiological processes
underlying AD (Akiyama et al., 2000; Kamer et al., 2008; Sardi
et al., 2011) and LOBD (Goldstein et al., 2009; Konradi et al., 2012;
Leboyer et al., 2012; Lee et al., 2013; Bauer et al., 2014a; Hope et al.,
2015), as well as many other neuropsychological illness, such as
depression and mania (Brydon et al., 2009; Dickerson et al., 2013;
Castanon et al., 2014; Singhal et al., 2014). These disorders seem
to be epigenetically linked to decrease transcriptional activity.
It has been reported that the frontal cortex of both LOBD and
AD patients exhibits an altered epigenetic regulation related to
neuroinflammation, synaptic integrity, and neuroprotection (Rao
et al., 2012). Oxidative stress contributes to the pathogenesis of
both diseases through similarmechanisms of neuroinflammation,
excitotoxicity, and upregulated brainmetabolism (Rao et al., 2010,
2011).Mood and cognition impairment are considered core prob-
lems in LOBD and AD, respectively. However, in recent years,
clinical features of AD, as well as cognitive deficits in LOBD, have
received more attention (Ng et al., 2008). Increased agitation and
aggression with cognitive and independence decline in AD can be
easily confused with LOBD (Zahodne et al., 2015). The following
psychiatric symptoms have been reported in AD in common with
the profile observed in LOBD: agitation, euphoria, disinhibition
overactivity without agitation, aggression, affective liability, dys-
phoria, apathy, impaired self-regulation, and psychosis (Albert
and Blacker, 2006).
1.2. Description of the Study
The study was registered as an observation trial1 in the ISRCTN
registry. It involved nearly one hundred subjects of age at recruit-
ment above 64 years, including healthy controls and patients with
diagnosis of AD or BD. The study included neuroimage data,
neuropsychological tests, and blood sample biomarkers. Classifi-
cation results based on neuroimage data have been reported else-
where (Graña et al., 2011; Besga et al., 2012), showing that features
extracted from fractional anisotropy coefficients of diffusion-
weighted images provided very high classification performance
between LOBD and AD patients. The hypothesis explored in the
work reported here is the feasibility of AD and LOBD discrimina-
tion using multivariate machine learning-based computer-aided
diagnosis (CAD) tools on a reduced set of clinical, cognitive,
and biological biomarker variables. We evaluated the classifi-
cation performance achieved using various feature sets com-
posed of combinations of variable categories, as well as a feature
selection based on the Welch’s t-test. Predictive CAD systems
have been proposed to improve diagnostic accuracy complement-
ing the neuropsychological assessments carried out by expert
clinicians (Sigut et al., 2007; Graña et al., 2011; Savio et al.,
2011; Westman et al., 2011; Termenon et al., 2013). Accurate
diagnosis is crucial to mitigate negative effects of inappropriate
treatments.
1http://www.controlled-trials.com/search?q=HS%2FPI2010001
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2. MATERIALS AND METHODS
Multivariate analysis methods (Westman et al., 2011) allow to
assess the joint significance of groups of biomarker measures.
They have been successfully applied to large dimensionality neu-
roimage data (Fung and Stoeckel, 2007; Salas-Gonzalez et al.,
2009). Achieved cross-validation classification accuracy, sensi-
tivity, specificity, and area under the ROC curve (AUC) pro-
vide the significance value for each combination of variables
considered as classification features. Approaches applying fea-
ture extraction by functional transformations of the data, such
as orthogonal partial least squares (Ramirez et al., 2010; West-
man et al., 2011), have achieved high classification performances.
However, these transformations do not allow to back-project the
contribution of each variable to classification success. In order
to reason about disease mechanisms and quality of biomark-
ers, we follow a feature selection approach, where variables are
selected according to their expected contribution to the classi-
fication success. Moreover, we report variable importance com-
puted on the basis of the contribution of each variable to the
construction of a specific CART classifier, as well as the Welch’s
t-test statistical significance of variable differences between
groups.
2.1. Subjects
Patients included in the study were referred to the psychiatric
unit at Alava University Hospital, Vitoria, from its catchment
recruitment area for clinical assessment of memory complaints.
The BD patients were in the euthymic state. No patient has pre-
vious BD diagnosis. These patients were all living in the commu-
nity. Selected subjects underwent a standard protocol, including
clinical, cognitive, and neuropsychological evaluations. Ninety-
five elderly subjects were included in the present study; Table 1
presents demographic details of the cohort. Sample size was con-
ditioned by the availability of funding to carry out MRI neu-
roimaging and biochemical tests. Reports on neuroimage results
are published elsewhere (Besga et al., 2011). The LOBD group
fulfills the DSM IV criteria and the AD group fulfills the NINDS-
ADRDA criteria for probable AD. Subjects with psychiatric dis-
orders (i.e., major depression) or other conditions (i.e., brain
tumors) were not considered for this study. The exclusion criteria
were ongoing infections, fever, allergies, or the presence of other
serious medical conditions (autoimmune, cardiac, pulmonary,
endocrine, and chronic infectious diseases, and neoplasms). Nei-
ther the patients nor the healthy control subjects were receiving
immunosuppressive drugs or vaccinations for at least 6months
prior to inclusion in the study or anti-inflammatory analgesics
2 days prior to the extraction of the blood sample. The ethics
committee of the Alava University Hospital, Spain, approved this
study. All patients gave their written consent to participate in
TABLE 1 | Demographic data (mean and SD for each group).
HC AD LOBD
M/F 15/11 20/17 9/23
Age 72.818.70 78.705.86 68.888.61
Education (0–5) 3.921.14 3.331.00 3.291.14
the study, which was conducted according to the provisions of
the Helsinki declaration. After written informed consent was
obtained, venous blood samples (10mL) were collected from the
volunteers, after which all themood scales and cognitive tests were
performed.
2.2. Variable Description
For each subject in the study, we have measured the following 3
categories of variables.
2.2.1. Neuropsychological Variables (NEURO)
Cognitive performance has been assessed with a battery of neu-
ropsychological tests covering the following cognitive domains:
executive function, learning and memory, and attention. The
index for each cognitive domain is the mean of the z-scores of the
tests covering that domain.
 Executive function: the executive function domainwas assessed
by combining measures from the following tests: Wisconsin
Card Sorting Test (WCST) (Heaton, 1981; Spreen and Strauss,
1998), Stroop Test-Interference (SCWT) (Golden, 1978), Trail
MakingTest part B (TMT-B) (Reitan andWolfson, 1985; Spreen
and Strauss, 1998), and Functioning Assessment Short Test
(FAS) (aka Controlled Oral Word Association Test) (Benton
and Hamsher, 1989).
 Learning and memory: Wechsler Memory Scale (WMS-III)
(Wechsler, 1997a,b) measuring five index scores: Auditory
Memory, Visual Memory, Visual Working Memory, Immediate
Memory, and Delayed Memory.
 Attention: the attention domain was assessed by combining the
scores of the Trail Making Test part A (TMT-A) (Reitan and
Wolfson, 1985), Stroop Colour–Word Test (SCWT) (Golden,
1978), and Digitsforward (DigitSpansubtest) (Wechsler Adult
Intelligence Scale) (WAIS-III) (Wechsler, 1997a) (Spanish ver-
sion by TEA, 1999).
2.2.2. Biological Markers (BIO)
Selected biological markers for analysis were reported as relevant
to LOBD and AD in published studies on inflammation based
pathology (Akiyama et al., 2000; Kamer et al., 2008; Goldstein
et al., 2009; Sardi et al., 2011; Lee et al., 2013; García-Bueno et al.,
2014). After extracting plasma from blood samples, inflammatory
cytokines interleukins 1 and 6 (IL-1 and IL-6) and tumor necrosis
factor alpha (TNFα) were determined by enzyme immunoassay
(EIA). Oxido-nitrosative parameters [nitrites and malondialde-
hyde (MDA)] were also analyzed in plasma samples. Cytokine
levels were measured by EIA using reagents in kit form for TNFα
(cat. 589201), Interleukin-1β (cat. 583311), and Interleukin 6 (cat.
501030) fromCayman Chemical Europe, Tallinn, Estonia. Plasma
levels of TNFα, IL1β, and IL6 were measured in a 96-well plate
and read at 405 nm following the manufacturer’s instructions.
Nitrites (NO2), the final and stable product of nitric oxide, were
measured using the Griess method, where samples are incu-
bated in acidic solution with sulfanilamide and N-(1-naphthyl)
ethylenediamine dihydrochloride (NEDA). The nitrites are con-
verted into a pink compound that is measured photometrically at
540 nm (Synergy 2, Biotek). Lipid peroxidation, the final product
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of the reaction of oxido-nitrosative molecules with lipidic com-
ponents of cells, was determined by Thiobarbituric Acid Reactive
Substances (TBARS) assay (Cayman Chemical Europe, Tallinn,
Estonia), based on the reaction of malondialdehyde (MDA) and
thiobarbituric acid (TBA) under high temperature (95°C) and
acidic conditions. The MDA-TBA adduct formed is measured
colorimetrically at 530–540 nm (Synergy 2, Biotek). PlasmaBDNF
levels were measured using a BDNF Sandwich ELISA Kit, accord-
ing to the manufacturer’s instructions (Millipore, USA, Cat. No.
CYT306). Serum NGF levels were measured with an enzyme-
linked immunosorbent assay (ELISA) method according to the
manufacturer’s instructions, using a ChemiKineTM NGF Sand-
wich ELISA Kit (Millipore, USA, Cat No CYT304). All samples
were assayed in duplicate. All plasma NF levels are expressed as
picograms per milliliter.
2.2.3. Clinical Observations (CLIN)
The Neuropsychiatric Inventory (NPI)2 (Cummings, 1997) was
developed to provide ameans of assessing neuropsychiatric symp-
toms and psychopathology of patients with Alzheimer’s disease
and other neurodegenerative disorders. The NPI assesses 10 (10-
item NPI) or 12 (2-item NPI) behavioral domains common
in dementia. These include Hallucinations, Delusions, Agita-
tion/aggression, Dysphoria/depression, Anxiety, Irritability, Dis-
inhibition, Euphoria, Apathy, Aberrant motor behavior, Sleep,
and night-time behavior change (12-item version only), Appetite
and eating change (12-item version only). Each NPI domain is
scored based on a standardized interview administered by the
clinician for frequency, severity, and associated caregiver distress.
2.3. Functional Assessment
Patients were functionally assessed by the Functional Assessment
Staging procedure (FAST) (Reisberg, 1988). Patients with greater
functional impairment show increments in cognitive loss. FAST
ranks patients in 16 stages. Stage 1 marks subjects without diffi-
culties, while Stage 7(f) marks patients unable to hold up his/her
head. The last eleven stages are subdivisions of FAST between the
late stages 6 and 7. FASTwas administered by the clinician leading
the study.
2.4. Population Comparison
We used the Welch’s t-test to assess the statistical significance of
variables differences between groups. It is a two-sample test used
to check the hypothesis that two populations have equal means.
Welch’s t-test is the adaptation of Student’s t-test for the case of two
population samples may have different variances. These tests are
often referred to as “unpaired” or “independent samples” t-tests,
as they are typically applied when the statistical units underlying
the two samples being compared are non-overlapping.
2.5. Classification Algorithms
Classification experiments were carried out in the Python pro-
gramming language, using specific classifier implementations
provided by scikit-learn3 (see text footnote 4) python package.
2http://www.dementia-assessment.com.au/behavioural/
3http://scikit-learn.org/stable/
We have applied the Support Vector Machines (SVM) (Vapnik,
1998), CART Decision Trees, and Random Forest (RF). Briefly
described, SVM build a discriminating function with optimal
generalization properties, which is a hyperplane built on the
basis of the support vectors at the boundaries between classes.
The kernel trick [e.g., radial basis function (RBF)] allows to
deal with not linearly separable classes. Parameter tuning (i.e.,
Gaussian function width) is performed independently at each
cross-validation fold when carrying out an assessment of classifier
performance. SVM and its libSVM4 implementation (Chang and
Lin, 2011) have become a standard classifier in the neuroscience
community (Burges, 1998; Tao et al., 2006; Fung and Stoeckel,
2007). CARTDecision Trees (Breiman et al., 1984; Quinlan, 1993)
are built by recursive data space partitions. A univariate (single
attribute) split is defined at each tree node using some criterion
(e.g., mutual information, gain-ratio, impurity gini index). Tree
leaves correspond to class a posteriori distribution of the training
data samples falling in this leave. Random Forests (RF) (Breiman,
2001) algorithm is an ensemble of classifiers, which has been
successfully applied in awide variety of classification tasks (Baran-
diaran et al., 2010). RF is a collection of decorrelated randomly
generated decision tree predictors, in which each tree casts a unit
vote to decide the most popular class of input x. A bootstrapped
training dataset is used to grow each individual tree. RF model
parameters are the number of trees, their maximum depth, and
the ratio of dimensionality reduction at each node. Finally, to
assess variable importance, we have computed for each variable
the average Gini impurity index (Breiman et al., 1984) of all the
nodes in a CART classifier where this variable is used for the
split, normalizing it such that the most important variable has
value 1.
2.5.1. Experimental Design
All variables are normalized computing their z-scores previ-
ous to classification experiments. In order to reduce circular-
ity effects, variable normalization was carried out independently
at each cross-validation folder. In order to evaluate the effect
of neuropshycological measures (NEURO), biological markers
(BIO), and clinical variables (CLIN) in differentiating HC from
individuals with AD and LOBD, we have applied multivariate
machine learning classification methods to each of the possible
contrasts in the study: (1) healthy controls versus Alzheimer’s
disease patients (HC vs. AD), (2) healthy controls versus Bipolar
disorder patients (HC vs. LOBD), and (3) Bipolar disorder ver-
sus Alzheimer’s disease patients (LOBD vs. AD). We evaluated
the performance of the classifier using a leave-one-out (LOO)
cross-validation algorithm, applying a 3 2-fold cross-validation
grid search for classifier optimal parameters tuning. To quantify
the results, we measured the following performance measures:
(a) accuracy ((TP+TN)/N), (b) specificity [TN/(FP+TN)], (c)
sensitivity [TP/(TP+ FN)], and (d) area under the ROC curve
(AUC) (Faraggi and Reiser, 2002; Joachims, 2005), where TP is
the number of true positives; TN is the number of true negatives;
FP is the number of false positives; and FN is the number of false
negatives.
4http://www.csie.ntu.edu.tw/~cjlin/libsvm/
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3. RESULTS
3.1. Statistical Group Comparison
Table 2 shows the Welch’s t-test p-values for the clinical, biolog-
ical, and neuropsychological variables, respectively, for each of
the possible contrasts. Entries highlighted in gray correspond to
statistically significant differences. Most of the clinical variables
have significant differences between groups, except Delusions and
Anxiety. Euphoria differences are significant in HC vs. LOBD.
Comparing LOBD vs. AD, only FAST and Agitation provide sig-
nificant differences. The biological biomarkers, on the other hand,
do not have any significant differences, with the exception of the
MDA and TNFα in the case of LOBD vs. AD. Neuropsycholog-
ical variables are statistically significant in the comparisons with
controls, but in the comparison LOBD vs. AD, only the memory
tests have significant differences.
3.2. Variable Importance
Figure 1 shows a plot of the feature importance of the variables
considered in the study for the LOBD vs. AD classification con-
trast. The most important variable in all experiments is FAST.
Overall, the feature importance values are in agreement with the
statistically significant differences presented in Table 2, provid-
ing a more precise ranking. Cognitive tests are the second most
important feature in the discrimination of HC vs. AD, whereas
the clinical aremore important discriminatingHC vs. LOBD, with
TABLE 2 | Welch’s t-test p-value for each behavioral, biological biomarker,
and aggregate neuropsychological variable (rows) per group contrast
(columns).
HC vs. AD HC vs. LOBD LOBD vs. AD
CLINICAL
FAST <0.001 <0.001 <0.001
TD1 0.022 0.045 0.871
TA1 0.009 <0.001 0.002
TDD 0.002 <0.001 0.145
TA2 0.002 <0.001 0.110
TE 0.325 0.008 0.026
TA3 <0.001 <0.001 0.579
TD2 0.065 0.356 0.618
TI 0.003 0.001 0.068
TC 0.003 0.096 0.230
TS 0.001 0.004 0.088
BIOLOGICAL BIOMARKER
BDNF 0.631 0.263 0.425
NGF 0.090 0.916 0.074
NO2 0.468 0.233 0.763
TNFα 0.087 0.691 0.021
IL6 0.646 0.147 0.170
IL1 0.539 0.781 0.477
MDA 0.304 0.052 <0.001
NEUROPSY
EF <0.001 <0.001 0.337
A <0.001 <0.001 0.804
M <0.001 <0.001 <0.001
Statistically significant entries (p< 0.01) are highlighted in gray.
TD1, total delusions; TA1, total agitation; TDD, total dysphoria/depression; TA2, total
anxiety; TE, total euphoria; TA3, total apathy; TD2, total disinhibition; TI, total irritability;
TC, total CMA; TS, total sleep; EF, executive functions; A, attention; M, memory.
memory domain ranking high. For the critical discrimination of
LOBDvs. AD, the clinical variables are themost informative; how-
ever, biological marker MDA ranks third while cognitive memory
domain ranks fifth. This is the only instance of high importance
ranking biological marker.
3.3. Classification
Classification performance results are presented in Tables 3 and 4
reporting accuracy, and AUC, respectively, for each classifier,
combination of variables and classification contrast. Comparing
classifier results, the CART provides the best results, though the
improvement relative to other classifiers does not achieve statisti-
cal significance (F-test, p> 0.01). This may be due to the fact that
small sample size penalizes the construction of large classifiers,
which are overparameterized. Comparison of results according
to variable category shows that clinical variables (CLIN) provide
the best results or contribute to them. On the other hand, the
biological biomarkers (BIO) are the ones that contribute less to
classification performance. Considering the contrast LOBD vs.
AD, the clinical variables provide the best results, though for some
classifiers, such as RBF SVM, the neuropsychological variables
contribute to improve results. The best results are obtained using
the set of variables selected according to their significance in a
Welch’s t-test (denoted CLIN+NEURO+BIO-Wt in the tables).
4. DISCUSSION
This study was designed to investigate the feasibility of discrimi-
nating between AD and LOBD (Lebert et al., 2008; Carlino et al.,
2013; Grande et al., 2014) using a wide range of clinical, neu-
ropsychological, and biological (inflammatory, oxido-nitrosative,
and neurotrophic) measures for this purpose. Previous studies
have attempted to discriminate between subjects with AD and
HC and between LOBD and HC, but there is no other study
FIGURE 1 | Normalized feature importances in the BD vs. AD
classification experiment.
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TABLE 3 | LOO accuracy estimation of the classifiers on the various
combinations of features for each classification contrast.
CART RF SVM
(rbf)
SVM
(lin)
LOBD
vs. AD
1. BIO 46.38 59.42 71.01 60.87
2. NEURO 66.67 71.01 68.12 55.07
3. BEHAV 85.51 84.06 79.71 84.06
4. BIO+NEURO 66.67 62.32 71.01 66.67
5. BIO+BEHAV 79.71 73.91 79.71 79.71
6. NEURO+BEHAV 79.71 81.16 82.61 84.06
7. NEURO+BEHAV+BIO 78.26 79.71 84.06 82.61
8. NEURO+BEHAV+BIO-Wt 90.26 86.67 89.06 87.51
HC vs.
AD
1. BIO 71.43 60.32 57.14 49.21
2. NEURO 88.89 93.65 87.30 84.13
3. BEHAV 95.24 95.24 93.65 95.24
4. BIO+NEURO 85.71 87.30 87.30 88.89
5. BIO+BEHAV 92.06 92.06 96.83 93.65
6. NEURO+BEHAV 93.65 96.83 95.24 96.83
7. NEURO+BEHAV+BIO 95.24 95.24 95.24 92.06
8. NEURO+BEHAV+BIO-Wt 96.24 97.21 97.21 97.21
HC vs.
LOBD
1. BIO 46.55 48.28 53.45 60.34
2. NEURO 75.86 77.59 79.31 82.76
3. BEHAV 89.66 89.66 91.38 91.38
4. BIO+NEURO 79.31 82.76 77.59 77.59
5. BIO+BEHAV 82.76 93.10 91.38 91.38
6. NEURO+BEHAV 82.76 94.83 93.10 93.10
7. NEURO+BEHAV+BIO 82.76 89.66 93.10 91.38
8. NEURO+BEHAV+BIO-Wt 91.76 95.76 94.10 94.38
Bold values are the maximum attained by a classifier per classification contrast.
BIO, blood biomarkers; BEHAV, clinical variables; NEURO, neuropsychological tests; Wt
variables are selected according to Welch’s t-test.
to our knowledge dealing with LOBD patients compared with
AD, when the differential diagnosis is more difficult (Aprahamian
et al., 2014). We have included HC vs. AD and HC vs. LOBD
contrasts inTables 2–4 to assess if the biomarkers are also useful to
discriminate them.We find that the results obtained are according
to the literature. We have found that the clinical variables carry
most of the diagnostic value; however, classification performance
can be improved by the consideration of the neuropsychological
variables and biological markers.
4.1. Clinical Variables
It has been observed that cognitive deficits affect the functionality
and global prognosis of LOBD patients (Kawas et al., 2003) as
occurs in patients with dementia. Besides cognitive performance,
behavioral disorders are also closely related to the overall func-
tionality of the patients. Non-cognitive symptoms have to be
considered as they may help the discrimination between LOBD
and AD. Our results in Figure 1 show that agitation, euphoria,
and disinhibition are the non-cognitive neuropsychological vari-
ables having the greatest discrimination power in the case AD
vs. LOBD. Nevertheless, the clinical variable that differentiates
more strongly between LOBDandAD is overall patient behavioral
functionality measured by FAST.
4.2. Neuropsychological Variables
Neuropsychological assessment is typically used for both descrip-
tive and diagnostic purposes. When used diagnostically, tests
TABLE 4 | LOO AUC estimation of the classifiers on the various combina-
tions of features for each classification contrast.
CART RF SVM
(rbf)
SVM
(lin)
LOBD
vs. AD
1. BIO 45.78 59.21 71.28 61.19
2. NEURO 66.60 71.28 68.58 55.15
3. BEHAV 85.64 83.87 79.81 83.87
4. BIO+NEURO 66.39 61.91 70.86 66.60
5. BIO+BEHAV 79.81 73.35 80.03 79.81
6. NEURO+BEHAV 80.24 80.74 82.73 84.08
7. NEURO+BEHAV+BIO 78.67 79.39 84.50 82.73
8. NEURO+BEHAV+BIO-Wt 89.57 86.39 88.25 87.33
HC vs.
AD
1. BIO 70.53 57.07 55.51 47.61
2. NEURO 88.25 92.88 87.47 84.20
3. BEHAV 95.37 95.37 94.02 94.80
4. BIO+NEURO 84.98 87.47 87.47 88.83
5. BIO+BEHAV 92.10 91.53 96.73 93.45
6. NEURO+BEHAV 93.45 96.73 95.37 96.15
7. NEURO+BEHAV+BIO 95.37 95.37 95.95 92.67
8. NEURO+BEHAV+BIO-Wt 97.33 98.17 98.17 97.77
HC vs.
LOBD
1. BIO 45.79 47.72 53.12 59.01
2. NEURO 76.32 77.16 79.45 82.93
3. BEHAV 89.54 89.90 91.47 91.11
4. BIO+NEURO 79.81 82.57 77.88 77.88
5. BIO+BEHAV 82.57 93.03 91.47 91.47
6. NEURO+BEHAV 82.93 94.23 93.75 93.39
7. NEURO+BEHAV+BIO 82.57 89.18 93.75 91.83
7. NEURO+BEHAV+BIO-Wt 91.37 96.38 95.55 95.55
Bold values are the maximum attained by a classifier per classification contrast.
BIO, blood biomarkers; BEHAV, clinical variables; NEURO, neuropsychological tests; Wt
variables selected according to Welch’s t-test.
provide information about how likely is that a particular individ-
ual has or will have a cognitive disorder. In relation to BD, various
studies have revealed cognitive impairment as part of its clinical
expression. In fact, some authors suggested that having been
diagnosed with BD is a significant predictor of cognitive decline
over time, further, cognitive dysfunction increases in the long
term (Lewandowski et al., 2011; Torrent et al., 2012). Although
there are limited data on the cognitive profile of LOBD (Car-
lino et al., 2013; Grande et al., 2014), cognitive deficits affecting
memory, attention, and executive function have been reported
(Robinson et al., 2006; Osher et al., 2011; Aprahamian et al., 2014).
Accordingly, when comparing LOBD patients with HC we found
that all these variables have statistically significant differences, as
shown in Table 2. Similar cognitive degradation is well known
in AD (Kawas et al., 2003; Albert and Blacker, 2006), and it is
confirmed by results in Table 2. The classification experiments
confirm that the set of neuropsychological variables (NEURO)
is useful to discriminate AD patients from controls, achieving
high accuracy (93.65%) and AUC (92.88%). However, they are
much less effective to discriminate LOBD patients from controls
and AD patients. The results of Welch’s t-test in Table 2 and
the variable importance results in Figure 1 confirm that memory
cognitive domain is essential in clinical practice for the detec-
tion and diagnosis of AD (Weintraub et al., 2012). Accordingly,
Figure 1 shows that memory domain tests have a high impor-
tance for AD vs. LOBD classification. Finally, we found that
memory is a key factor in differential diagnosis between LOBD
and AD.
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4.3. Blood Biomarkers
Besides the similarity of some symptoms, AD and LOBD share
pathophysiological features that might difficult differential diag-
nosis. Peripheral markers related to inflammation, oxidative
stress, and neurotrophins have been related to clinical symp-
toms, cognitive decline, and illness severity in BD (Barbosa et al.,
2012; Martinez-Cengotitabengoa et al., 2014), as well as in AD
(Berridge, 2013). In our study, all blood biomarkers, except IL1,
were lower in the plasma of LOBD group than in AD group,
although only MDA levels revealed statistical significant differ-
ence in the Welch’s t-test. This finding agrees with a signifi-
cant decrease in BDNF and IL-6 in BD patients at later stage
compared to its early stage, while, inversely, TNFα has a sig-
nificant increase at the BD later stage (Kauer-Sant’Anna et al.,
2009; Grande et al., 2014). All these findings may suggest that the
group of LOBD patients have more inflammation. No discrim-
inant variable has been found from the collection of biological
biomarkers (BIO) in our classification experiments. There are
numerous reports of inflammation and excess oxidation within
the brain of patients, but outside the CNS, the evidence is less
definite and results of studies are often contradictory. It has
been suggested that inflammation and oxidative stress do not
cause AD or LOBD by themselves, but probably during aging,
they reinforce many interdependent factors related to these com-
plex neuropsychiatric disorders (Forcada et al., 2014). It is well
known that brain aging involves complex structural and molec-
ular processes that provide a misbalance between protective and
degenerative factors, predisposing the brain to higher risk of
acquiring neurodegenerative diseases (Lewandowski et al., 2011).
Nevertheless, the inclusion of MDA in the Welch’s t-test fea-
tures produces a great improvement in classification performance,
reaching accuracy 90.26 and AUC 89.57. This is a surprising
fact because inflammation is a common effect not a differential
effect.
4.4. Limitations
The sample is not well balanced; there are diverse numbers of
AD, LOBD, and HC. The feminine LOBD sample is much larger.
Old age patients suffer from multimorbidity, which is a source of
confusion for blood plasma biomarkers.
5. CONCLUSION
We have found that a small set of variables, including an oxidative
stress biomarker (i.e.,MDA), allows gooddiscrimination of LOBD
and AD. Besides the potential construction of a CAD system
upon larger databases, these findings could help in identifying
new therapeutic routes for treatment and diagnosis.
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